Dr. Quincy Siu Chung Chu, MD
Claim this profileCross Cancer Institute
Studies Tumors
Studies Solid Tumors
2 reported clinical trials
4 drugs studied
Area of expertise
1Tumors
Stage IV
Stage III
ALK positive
2Solid Tumors
Stage IV
Stage III
ALK positive
Affiliated Hospitals
Clinical Trials Quincy Siu Chung Chu, MD is currently running
BT8009 + Pembrolizumab
for Solid Tumors
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Part B), Safety and tolerability (Part C), and characterization of the pharmacokinetics (Part D).
Recruiting1 award Phase 1 & 214 criteria
NVL-655
for NSCLC
This trial is testing a new drug called NVL-655 to see if it is safe and effective for patients with advanced ALK-positive lung cancer and other solid tumors. The drug works by blocking a protein that helps cancer cells grow. The study focuses on patients who have specific genetic changes and may not respond well to standard treatments. Newer treatments have been shown to improve outcomes in ALK-translocated lung cancer compared to older treatments.
Recruiting1 award Phase 1 & 27 criteria
More about Quincy Siu Chung Chu, MD
Clinical Trial Related4 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Quincy Siu Chung Chu, MD has experience with
- BT8009
- Nivolumab
- Pembrolizumab
- NVL-655
Breakdown of trials Quincy Siu Chung Chu, MD has run
Ovarian Neoplasms
Breast Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Quincy Siu Chung Chu, MD specialize in?
Quincy Siu Chung Chu, MD focuses on Tumors and Solid Tumors. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are Stage III.
Is Quincy Siu Chung Chu, MD currently recruiting for clinical trials?
Yes, Quincy Siu Chung Chu, MD is currently recruiting for 2 clinical trials in Edmonton Alberta. If you're interested in participating, you should apply.
Are there any treatments that Quincy Siu Chung Chu, MD has studied deeply?
Yes, Quincy Siu Chung Chu, MD has studied treatments such as BT8009, Nivolumab, Pembrolizumab.
What is the best way to schedule an appointment with Quincy Siu Chung Chu, MD?
Apply for one of the trials that Quincy Siu Chung Chu, MD is conducting.
What is the office address of Quincy Siu Chung Chu, MD?
The office of Quincy Siu Chung Chu, MD is located at: Cross Cancer Institute, Edmonton, Alberta T6G 1Z2 Canada. This is the address for their practice at the Cross Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.